A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron ® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer

Ovarian cancer has no definitive second line therapeutic options, and largely recurs in the peritoneal cavity. Locoregional immune therapy using both interferons and monocytes can be used as a novel approach. ...

Source: Journal of Translational Medicine - July 16, 2018 Category: Research Authors: Daniel S. Green, Ana T. Nunes, Virginia David-Ocampo, Irene B. Ekwede, Nicole D. Houston, Steven L. Highfill, Hanh Khuu, David F. Stroncek, Seth M. Steinberg, Kathryn C. Zoon and Christina M. Annunziata Tags: Protocol Source Type: research